These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27317471)

  • 1. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
    Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
    AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
    Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
    Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
    Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
    Shin KH; Choi MH; Lim KS; Yu KS; Jang IJ; Cho JY
    Clin Pharmacol Ther; 2013 Nov; 94(5):601-9. PubMed ID: 23784264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
    Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
    Lee S; Lee Y; Kim AH; Yoon S; Lee J; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2021 Feb; 36():100374. PubMed ID: 33348239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
    Tahara H; Watanabe M; Hasegawa M
    Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
    Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
    Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.
    Koup JR; Anderson GD; Loi CM
    J Clin Pharmacol; 1998 Sep; 38(9):815-8. PubMed ID: 9753209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
    Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
    Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans.
    Furuta T; Suzuki A; Mori C; Shibasaki H; Yokokawa A; Kasuya Y
    Drug Metab Dispos; 2003 Nov; 31(11):1283-7. PubMed ID: 14570755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
    Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
    AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.